Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mamuran (also known as Mamuran Zhixie Capsules or Ma-Mu-Ran) is a Traditional Uyghur Patent Medicine (TUPM) approved by the China Food and Drug Administration (CFDA) for the treatment of diarrhea, abdominal pain, vomiting, and indigestion associated with acute enteritis, bacillary dysentery, and ulcerative colitis. It is a multi-herb compound preparation composed of 14 traditional medicines, including Coptidis Rhizoma, Draconis Sanguis, Olibanum, Turkish Galls, Bambusae Concretio Silicea, Semen Plantaginis Psyllii, Chebulae Fructus Immaturus, Fructus Berberis, Fructus Coriandri, Chebulae Fructus, Terminalise Belliricae Fructus, Flos Granati, Granati Pericarpium, and Gummi Tragacanthae. Mamuran exerts its therapeutic effects by regulating host metabolism and modulating the gut microbiota, particularly by restoring the abundance of beneficial bacteria such as Lactobacillus and Bifidobacterium. Its primary active components, berberine hydrochloride and gallic acid, provide potent anti-inflammatory, antimicrobial, and mucosal protective properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mamuran.